Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage. Tiziana Life Sciences PLC is based in London, United Kingdom.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-15.40M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.96 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -- |
Return on Assets (Trailing 12 Months) | -- |
Current Ratio (Most Recent Fiscal Quarter) | -- |
Quick Ratio (Most Recent Fiscal Quarter) | -- |
Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $0.19 |
Earnings per Share (Most Recent Fiscal Quarter) | -- |
Earnings per Share (Most Recent Fiscal Year) | $-0.15 |
Diluted Earnings per Share (Trailing 12 Months) | -- |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | -- |
Free Float | -- |
Market Capitalization | -- |
Average Volume (Last 20 Days) | 0.31M |
Beta (Past 60 Months) | 0.82 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 39.82% |
Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |